Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel

Publisher： Karger

E-ISSN： 1662-6575|9|1|56-61

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.1, 2016-01, pp. : 56-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-01 ,pp. : 43-46

Karger

Access to resources Recommend Favorite

Lanreotide Autogel®® in acromegaly and neuroendocrine tumors

By Caron Philippe  

Therapy, Vol. 4, Iss. 1, 2007-01 ,pp. : 9-29

Future Medicine

Access to resources Recommend Favorite

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel®: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 673-680

Karger

Access to resources Recommend Favorite

Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal

By  

COLORECTAL DISEASE, Vol. 17, Iss. 8, 2015-08 ,pp. : 698-703

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab for the Treatment of Non-Resectable Pseudomyxoma peritonei Associated with Mucinous Ovarian Tumor of Low Malignant Potential – A Comparison of Two Cases

By  

Case Reports in Oncology, Vol. 3, Iss. 1, 2009-01 ,pp. : 1-8

Karger

Access to resources Recommend Favorite